By Editorial Staff
As the medical community navigates an era of unprecedented volatility in research funding and clinical innovation, the voices of those living with Metastatic Breast Cancer (MBC) have never been more critical. Dr. Kelly Shanahan, President of METAvivor, recently issued a comprehensive update that highlights the organization’s ongoing commitment to advocacy, the acceleration of vital research, and the evolving landscape of FDA drug approvals. From the unpredictability of living with stage IV cancer to the high-stakes world of international oncology conferences, the message remains clear: the patient voice is not just a suggestion—it is an essential component of modern medicine.
I. Main Facts: Bridging the Gap Between Research and Reality
The landscape for metastatic breast cancer research is currently defined by a surge in demand for resources, contrasted by a climate of fiscal uncertainty for federal research grants. METAvivor has become a primary pillar of support, filling the gaps left by traditional funding avenues.
In her recent correspondence, Dr. Shanahan noted that the organization’s Scientific Advisory Board (SAB) recently reviewed 200 Letters of Intent (LOIs) for the latest grant cycle. This figure represents a doubling of submissions compared to previous years, a clear indicator of the growing instability in federal research funding. Dr. Stuart Martin, a longstanding member of the SAB, noted that METAvivor’s efforts are essential to ensuring that metastasis research does not stall during these challenging economic times.
The selection process for these grants is rigorous, utilizing a dual-review system that incorporates both scientific experts and Patient Advocate Reviewers (PARs). By integrating the lived experience of patients into the scientific evaluation process, METAvivor ensures that the research being funded is not only academically sound but also clinically meaningful to those who need it most.
II. Chronology of Advocacy: From Tahoe to Chicago and Beyond
The timeline of advocacy for the MBC community is fast-paced and geographically diverse. Dr. Shanahan’s schedule serves as a microcosm of the global fight against cancer:
- Late May: Dr. Shanahan prepares to take the main stage at the American Society of Clinical Oncology (ASCO) conference in Chicago. Her presentation, titled "Elevating the Patient Voice: Choosing the Right Patient-Centered Endpoints in Modern Clinical Trials," challenges the medical establishment to redefine success in clinical trials through the lens of patient priorities.
- Early June: Following her presentation in Chicago, Dr. Shanahan will travel to Austin, Minnesota, to address the Hormel Institute’s Global Cancer Consortium. This event will focus on the latest breakthroughs in metastasis research, with a notable keynote address from Dr. Danny Welch on the fundamental hallmarks of metastatic progression.
- Mid-June: The advocacy circuit continues with a focus on regulatory transparency, specifically regarding the FDA’s Oncologic Drugs Advisory Committee (ODAC) and the evolving interpretation of data concerning investigational drugs like camizestrant.
III. Supporting Data: The Regulatory Landscape
The regulatory path for new cancer therapies is rarely linear. A recent point of contention involves the FDA’s decision regarding the transition from traditional endocrine therapies (AI + CDK4/6 inhibitors) to investigational combinations (camizestrant + CDK4/6 inhibitors) in patients showing an ESR1 mutation before imaging confirms disease progression.
METAvivor leadership, including board members Janice Cowden and Lynda Weatherby, have engaged in deep-dive discussions on the Live from Stage 4 podcast series. These episodes provide a platform for "news for us, by us," breaking down complex regulatory decisions into digestible insights for the patient community.
While the FDA has maintained a cautious approach to the SERENA-6 trial data, the European Medicines Agency (EMA) has shown more optimism, recommending approval for camizestrant. This divergence highlights the global nature of cancer research and the importance of continued, rigorous review of new pharmacological data.
Despite these regulatory hurdles, the month of May brought significant milestones in therapeutic development, providing a tangible beacon of hope for the community:
- Veppanu (vepdegestrant): FDA approval for ER+, HER2- MBC patients presenting with an ESR1 mutation.
- Datroway (datopotamab deruxtecan): A landmark approval as a first-line treatment for metastatic Triple-Negative Breast Cancer (TNBC) patients who are ineligible for immunotherapy.
- Enhertu (trastuzumab deruxtecan): An expansion of indications into the early-stage HER2+ setting, serving as a prophylactic measure to reduce the incidence of future metastatic progression.
IV. Official Responses and the "Patient-Centered" Paradigm
The core of Dr. Shanahan’s message—and indeed the mission of METAvivor—is the demand for a "bigger table." For too long, the design of clinical trials has been dominated by purely quantitative endpoints. The movement to include patient-centered endpoints is a direct response to the frustration of those living with the disease.
"How to design trials that are meaningful to people with cancer: ask us," is the central thesis of Dr. Shanahan’s upcoming ASCO presentation. By invoking the iconic, if unconventional, wisdom of the Spice Girls—"tell me what you want, what you really, really want"—Dr. Shanahan highlights the need for researchers to bypass assumptions and engage in direct, honest dialogue with patients.
Researchers at the Hormel Institute and beyond are increasingly being urged to integrate patient experts into their project planning phases. The goal is to move beyond the "bench-to-bedside" model and toward a "patient-to-bench" model, where the lived experience dictates the clinical priorities.
V. Implications: The Future of Metastasis Research
The implications of these developments are twofold: financial and systemic.
The Financial Imperative
With the number of grant applications doubling, the burden on philanthropic organizations like METAvivor has never been higher. The stability of metastatic research is currently tied directly to private donations. As Dr. Shanahan frequently emphasizes, without the continued support of the public, the life-saving momentum of these studies will inevitably slow. The call to action for donors is not merely for charitable support, but for an investment in a research ecosystem that is increasingly being abandoned by traditional funding streams.
Systemic Reform
The move toward incorporating patient advocates as reviewers (PARs) is a systemic shift that is beginning to pay dividends. By ensuring that every stage of the research process—from the initial grant application to the final FDA regulatory filing—is scrutinized by those who understand the physical and psychological toll of MBC, the scientific community is producing better, more relevant outcomes.
Furthermore, the rise of specialized media like the Live from Stage 4 podcast signifies a maturation of the patient-advocacy movement. Patients are no longer passive recipients of medical information; they are active analysts of regulatory policy, clinical trial design, and emerging pharmacologic data.
Conclusion: A Delicate Balance of Hope and Vigilance
Living with metastatic breast cancer is a state of constant, fluid transition. As Dr. Shanahan aptly notes, life with MBC can change "on a dime," much like the weather in the mountains of Tahoe. However, the progress made in May alone—with three major drug approvals—demonstrates that the research pipeline is alive and yielding results.
As the community looks toward the findings presented at ASCO and the ongoing research at the Hormel Institute, the message is one of cautious optimism. The scientific community is listening, the regulatory agencies are being challenged to evolve, and the patient voice is finally being recognized as the most valuable asset in the oncology toolkit.
For those interested in contributing to this momentum, whether as a researcher, a Patient Advocate Reviewer, or a donor, the opportunity to participate in this life-saving work is open. As Dr. Shanahan concludes her report, she leaves the community with a poignant reminder of the personal stakes involved: the hope for effective clinical trials and the continued effort to represent the MBC community on the global stage.
The fight is far from over, but with every grant approved, every trial designed with the patient in mind, and every voice raised in advocacy, the horizon for those living with metastatic breast cancer becomes just a little bit brighter.
About the Author
